🧠 This Week in Neuroscience: Major Depressive Disorder, Parkinson’s Breakthroughs, Gene Therapy Pauses and More
Explore the latest breakthroughs in neuroscience! This week’s update covers new clinical trials for depression, cutting-edge Parkinson’s cell therapies, gene therapy concerns in Duchenne muscular dystrophy, and advancements in pain relief. With innovations in FDA approvals, breakthrough designations, and ongoing research—this roundup brings you closer to the future of brain science and treatment possibilities.
📌 What’s Inside This Week’s Update
💥 Suven Life Sciences begins Phase-2b trial for Ropanicant in Major Depressive Disorder
🧠 S.BIOMEDICS reports positive 12-month data for Parkinson’s A9-DPC cell therapy
🔥 AlzeCure’s ACD440 shows strong efficacy in Phase-2a neuropathic pain trials
💉 Eisai presents four-year Lecanemab data for Alzheimer’s at upcoming conference
🇨🇦 Knight Therapeutics submits New Drug Application for CREXONT® in Canada for Parkinson’s
⚡ Praxis Precision receives FDA Breakthrough Therapy Designation for relutrigine in epileptic encephalopathies
🛑 Sarepta pauses Elevidys gene therapy shipments after FDA concerns
💸 Illimis Therapeutics raises $42 million to advance CNS and immune disease therapies
From new clinical trials to exciting pain relief innovations, this week’s update underscores the transformative potential of neuroscience in treating some of the most challenging diseases.
📢 Stay Ahead in Neuroscience Research!
✅ Like, share, and subscribe for weekly updates on neuroscience and neurodegenerative breakthroughs
#Neuroscience #Parkinsons #Alzheimers #GeneTherapy #PainRelief #ClinicalTrials #NeuroscienceBreakthroughs #FDAnews #CNSResearch #LucidQuest #ParkinsonsResearch #NeurodegenerativeDiseases #TherapeuticAdvancements #BiotechInnovation #HealthcareConsulting #NeuroscienceUpdates